Skip to main content
SpringerLink
Log in

CAR T cells in multiple myeloma: Where we stand and where we might be going

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

In this review we highlight the current developments in Chimeric antigen receptor (CAR) T cell therapy for myeloma. Two advanced products (idecabtagene vicleucel and ciltacabtagene autoleucel) targeting B‑cell maturation antigen have already been approved by the US Food and Drug Administration (FDA). In heavily pretreated myeloma patients, response rates between 82 and 98% and a median progression-free survival between 12 and > 24 months have been achieved. Currently these two products are being investigated in earlier lines of therapy. Beside BCMA, other targets have been selected for CAR T cell therapy in myeloma, with advanced constructs targeting two antigens. We highlight current strategies to improve CAR T cell effectiveness and safety and give a personal outlook where cellular immunotherapy in myeloma might be heading.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Teoh PJ, Chng WJ. CAR T‑cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84.

    Article  Google Scholar 

  2. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

    Article  CAS  Google Scholar 

  3. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigen—directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 549. 2021.

    Google Scholar 

  4. Mateos MV, Weisel K, Martin T, et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective study. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 550. 2021.

    Google Scholar 

  5. Van de Donk NW, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T‑cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302–18.

    Article  Google Scholar 

  6. Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR‑T cells in multiple myeloma. Blood Rev. 2022; https://doi.org/10.1016/j.blre.2022.100929.

    Article  PubMed  Google Scholar 

  7. Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953–60.

    Article  CAS  Google Scholar 

  8. Mailankody S, Diamonte C, Fitzgerald L, et al. Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 827. 2021.

    Google Scholar 

  9. Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR‑T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283.

    Article  CAS  Google Scholar 

  10. Mei H, Li C, Jiang H, et al. A bispecific CAR‑T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161.

    Article  CAS  Google Scholar 

  11. Van de Donk NW, Usmani SZ, Yong K. CAR T‑cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446–e61. https://doi.org/10.1016/S2352-3026(21)00057-0.

    Article  PubMed  Google Scholar 

  12. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T‑cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24.

    Article  CAS  Google Scholar 

  13. Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B‑cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38(15_suppl):8504.

    Article  Google Scholar 

  14. Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 548. 2021.

    Google Scholar 

  15. Mailankody S, Liedtke M, Sidana S, et al. Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma. Abstract. 63rd ASH Annual Meeting & Exposition. Vol. 651. 2021.

    Google Scholar 

  16. Pont MJ, Hill T, O’Cole G, et al. γ‑Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585–97.

    Article  Google Scholar 

  17. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T‑cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37.

    Article  CAS  Google Scholar 

  18. Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11(499):eaau5907.

    Article  Google Scholar 

  19. Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR‑T cell therapy. Nat Med. 2021;27(12):2099–103.

    Article  Google Scholar 

  20. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67.

    Article  Google Scholar 

  21. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.

    Article  Google Scholar 

  22. Xie G, Dong H, Liang Y, et al. CAR-NK cells: a promising cellular immunotherapy for cancer. eBioMedicine. 2020;59:102975. https://doi.org/10.1016/j.ebiom.2020.102975.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Moscarelli J, Zahavi D, Maynard R, Weiner LM. The next generation of cellular immunotherapy: CAR-NK cells. Transplant Cell Ther. 2022; https://doi.org/10.1016/j.jtct.2022.06.025.

    Article  PubMed  Google Scholar 

  24. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251–8.

    Article  CAS  Google Scholar 

  25. Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–27.

    Article  CAS  Google Scholar 

  26. Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310.

    Article  CAS  Google Scholar 

  27. Poels R, Drent E, Lameris R, et al. Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. Int J Mol Sci. 2021;22(3):1096.

    Article  CAS  Google Scholar 

  28. Leivas A, Valeri A, Codoba L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11(8):146.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Center for Oncology and Hematology, Klinik Ottakring, Montleartstr. 37, 1160, Vienna, Austria

    Niklas Zojer &  Martin Schreder

  2. Wilheminen Cancer Research Institute, c/o Department of Internal Medicine I, Center for Oncology and Hematology, Klinik Ottakring, Vienna, Austria

    Heinz Ludwig

Authors
  1. Niklas Zojer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Schreder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heinz Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niklas Zojer.

Ethics declarations

Conflict of interest

N. Zojer received honoraria (ad boards, lectures) from Janssen, BMS, Celgene, Amgen, Sanofi, Takeda. M. Schreder received honoraria (ad boards, lectures) from Janssen, BMS, Amgen, Sanofi, AbbVie, Pfizer. H. Ludwig received honoraria (ad boards and/or lectures) from Janssen, Sanofi, Takeda, GSK, BMS, Abbvie.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zojer, N., Schreder, M. & Ludwig, H. CAR T cells in multiple myeloma: Where we stand and where we might be going. memo 15, 185–189 (2022). https://doi.org/10.1007/s12254-022-00825-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00825-6

Keywords

Search

Navigation